German biotech CureVac NV said on Wednesday that its vaccine CureVac was only 47 percent effective against COVID-19 disease severity.
“CVnCoV demonstrated an interim vaccine efficacy of 47 percent against COVID-19 disease of any severity and did not meet prespecified statistical success criteria,” German biotech CureVac said.
German biotech CureVac also cited the “unprecedented context of at least 13 variants circulating within the study population subset assessed” for the disappointing result, as well as varying responses across different age groups.
Franz-Werner Haas, CureVac’s chief executive meanwhile said that the unprecedented broad diversity of variants was challenging.
“While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging,” Haas said.
“As we are continuing toward the final analysis with a minimum of 80 additional cases, the overall vaccine efficacy may change,” Haas added.
CureVac’s trials involved more than 40,000 people and took place across ten countries in Europe and Latin America.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.